CN119367476A - 一种抗炎散结的中药组合物及其制备方法 - Google Patents
一种抗炎散结的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN119367476A CN119367476A CN202411395437.XA CN202411395437A CN119367476A CN 119367476 A CN119367476 A CN 119367476A CN 202411395437 A CN202411395437 A CN 202411395437A CN 119367476 A CN119367476 A CN 119367476A
- Authority
- CN
- China
- Prior art keywords
- parts
- inflammatory
- radix
- resolving
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 101
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 24
- 210000000582 semen Anatomy 0.000 claims abstract description 22
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 21
- 235000010447 xylitol Nutrition 0.000 claims abstract description 21
- 239000000811 xylitol Substances 0.000 claims abstract description 21
- 229960002675 xylitol Drugs 0.000 claims abstract description 21
- 241000756943 Codonopsis Species 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 244000276331 Citrus maxima Species 0.000 claims abstract description 8
- 235000001759 Citrus maxima Nutrition 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims abstract 2
- 240000008669 Hedera helix Species 0.000 claims abstract 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract 2
- 108010052008 colla corii asini Proteins 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims description 29
- 244000197580 Poria cocos Species 0.000 claims description 22
- 235000008599 Poria cocos Nutrition 0.000 claims description 22
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims description 21
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 claims description 21
- 241000046198 Triteleia hyacinthina Species 0.000 claims description 21
- 241000132012 Atractylodes Species 0.000 claims description 20
- 244000018633 Prunus armeniaca Species 0.000 claims description 20
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 20
- 241000245665 Taraxacum Species 0.000 claims description 20
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 20
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 19
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 19
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 19
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 19
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 19
- 108010010803 Gelatin Proteins 0.000 claims description 19
- 240000000691 Houttuynia cordata Species 0.000 claims description 19
- 241000237502 Ostreidae Species 0.000 claims description 19
- 241000270666 Testudines Species 0.000 claims description 19
- 229920000159 gelatin Polymers 0.000 claims description 19
- 239000008273 gelatin Substances 0.000 claims description 19
- 235000019322 gelatine Nutrition 0.000 claims description 19
- 235000011852 gelatine desserts Nutrition 0.000 claims description 19
- 235000020636 oyster Nutrition 0.000 claims description 19
- 235000013717 Houttuynia Nutrition 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 244000077995 Coix lacryma jobi Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241001412627 Adenophora liliifolia Species 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 240000006766 Cornus mas Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 21
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 241000209020 Cornus Species 0.000 description 13
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 241000405414 Rehmannia Species 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 235000021251 pulses Nutrition 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 208000031513 cyst Diseases 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000007012 clinical effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 206010006272 Breast mass Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 241000759833 Cornus officinalis Species 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241001633574 Adenophora stricta Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010063088 Breast fibroma Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010056342 Pulmonary mass Diseases 0.000 description 2
- 208000009453 Thyroid Nodule Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000008494 nodular goiter Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗炎散结的中药组合物及其制备方法,属于中医药技术领域,包括如下原料:化橘红、金银花、茯苓、薏苡仁、鱼腥草、以生地、白扁豆、佛手、苦杏仁、牡蛎、白术、黄精、白芷、蒲公英、昆布、鳖甲、阿胶、山萸肉、山药、党参、沙参、木糖醇。本发明的有益效果是:本发明处方组成合理,不含有毒药材,也无配伍禁忌,具有很好的抗炎散结的作用。通过调整君药化橘红、金银花的重量份比例配伍后,能够协同抑制由LPS诱导的炎症反应中TNF‑α、iL‑6的表达。且原料均为天然舒缓成分,药效温和,安全合理,工艺简单,临床疗效可靠,应用过程中未发生明显毒副作用和不良反应,确保临床疗效,质量可控。
Description
技术领域
本发明涉及中医药技术领域,具体而言,涉及一种抗炎散结的中药组合物及其制备方法。
背景技术
中医理论中的经络学说认为人体内部存在经络系统,炎症时经络受阻,导致炎症区域血液循环不畅,气血瘀滞。中医药的抗炎散结治疗理念主要是通过调理经络,促进气血流通,改善局部状况,从而加速炎症的消退和结节的消散。另根据临床经验,气血运行问题多归因于脏腑的虚弱衰惫,选方多通过使用如党参、白术、茯苓等为传统经典方剂,起到健脾益气,扶正驱邪,寓通于补的作用。在中医理论体系中,与抗炎散结相关的疾病广泛多样,主要涉及的系统与疾病包括呼吸系统疾病如急性咽喉炎、急性扁桃体炎等,消化系统疾病如胆管炎、痢疾等,运动系统疾病如关节肿痛、风湿性关节炎等。
目前针对上述与抗炎散结相关疾病治疗的主要原则是祛湿化痰、清热解毒等,通过配伍用多种作用温和的成分从多个方向调节,如用含植物激素、甾体或类似物的药物调节身体的应激状态,部分阻断炎症介质分子花生四烯酸衍生物的产生;用含环氧化酶和脂氧化酶抑制剂的药物适当阻断炎症介质分子的生成;用富含黄酮和酚类成分的药物抗击氧自由基,调节细胞环境中的氧化-抗氧化状态;用增强免疫功能的药物促进炎性组织被破坏和吞噬;用促进血循环、利尿和通便的药物促使被破坏的炎症组织、代谢废物转移和排出体外。中医历来有慢性病缓病缓治的观念,即对于慢性疾病,以培养机体的正气为主,让机体逐渐恢复;而不是主张用大剂量的药物攻击以求迅速缓解病情。这些观念正好符合调节细胞生物内环境,培育机体自身的调节功能的观念。长期重用和单用某一药物的某一两种成分的方法,实际上又会导致新的环境不平衡,这对慢性病的治疗,实际上是不利的。临床上西医并没有相应疾病与之对应,人们出现上述症状时多就诊于消化内科、口腔科,治疗方法主要是对症治疗,给予促进胃肠动力药,清热解毒的中成药等,疗效并不确切,且缠绵难愈。
有鉴于此,本发明人针对这一需求展开深入研究,遂有本案产生。
发明内容
为解决上述问题,本发明提供了一种抗炎散结的中药组合物及其制备方法,具有抗炎散结的作用,以达到治疗与抗炎散结相关的疾病并提高相关疾病临床治疗效果。
本发明提供的一种抗炎散结的中药组合物,包括如下原料:化橘红、金银花、茯苓、薏苡仁、鱼腥草、以生地、白扁豆、佛手、苦杏仁、牡蛎、白术、黄精、白芷、蒲公英、昆布、鳖甲、阿胶、山萸肉、山药、党参、沙参、木糖醇。
优选地,按重量份计,包括如下原料:化橘红150~350份,金银花150~350份,茯苓100~300份,薏苡仁100~300份,鱼腥草100~300份,生地30~120份,白扁豆30~120份,佛手30~120份,苦杏仁30~120份,牡蛎30~120份,白术30~120份,黄精30~120份,白芷30~120份,蒲公英20~80份,昆布20~80份,鳖甲20~80份,阿胶5~60份,山萸肉5~60份,山药5~60份,党参5~30份,沙参5~30份,木糖醇5~30份。
优选地,按重量份计,包括如下原料:化橘红200~300份,金银花200~300份,茯苓150~250份,薏苡仁150~250份,鱼腥草150~250份,生地50~100份,白扁豆50~100份,佛手50~100份,苦杏仁50~100份,牡蛎50~100份,白术50~100份,黄精50~100份,白芷50~100份,蒲公英30~70份,昆布30~70份,鳖甲30~70份,阿胶10~50份,山萸肉10~50份,山药10~50份,党参10~20份,沙参10~20份,木糖醇10~20份。
优选地,按重量份计,包括如下原料:化橘红200~250份,金银花250~300份,茯苓180~220份,薏苡仁180~220份,鱼腥草180~220份,生地50~80份,白扁豆50~80份,佛手50~80份,苦杏仁50~80份,牡蛎50~80份,白术50~80份,黄精50~80份,白芷50~80份,蒲公英30~60份,昆布30~60份,鳖甲30~60份,阿胶10~30份,山萸肉10~30份,山药10~30份,党参10~15份,沙参10~15份,木糖醇10~15份。
本发明还提供了上述抗炎散结的中药组合物在制备抗炎结散的药物中的应用。
本发明还提供了一种抗炎散结的药物,包括上述的抗炎散结的中药组合物和药学上可接受的辅料。
优选地,上述药物的剂型为中药汤剂、煎剂、颗粒剂、丸剂、胶囊剂、片剂、茶剂、混悬剂、散剂或口服液。
优选地,本发明还提供了上述药物的制备方法,所述药物为丸剂,其制备方法如下:
步骤一,按重量份配比称取原料药,净选,烘干,切制,粉碎,过筛,混合均匀;
步骤二,将原料药于清水中浸泡0.5~1h,加热到80-100℃,反复煎煮1~3次,每次加入水的重量为所有原料总重量的10~20倍,加热煎煮时间为1.5~2h,最后合并滤液;
步骤三,静置沉淀滤液后取上清液,浓缩成清膏组合物,喷雾干燥,得到清膏粉,加入炼蜜,按照常规工艺,制成丸剂。
采用本发明技术方案产生的有益效果如下:
本发明中药组合物中以化橘红、金银花共为君药,化橘红祛湿化痰、宽中散结,金银花清热解毒、疏散抗炎;以茯苓、薏苡仁、鱼腥草共为臣药,茯苓、薏苡仁均可利水渗湿、抗炎抗氧化,鱼腥草清热解毒、抗炎散结;以生地、白扁豆、佛手、苦杏仁、牡蛎、白术、黄精、白芷共为佐药,佛手疏肝理气和胃、燥湿化痰,生地清热凉血、养阴生津,白扁豆健脾化湿、和中消暑,苦杏仁止咳平喘、润肠通便,牡蛎止汗涩精、化痰软坚,白术健脾益气、燥湿利水,黄精补气养阴、健脾润肺,白芷解表散寒、祛风止痛;以蒲公英、昆布、鳖甲、阿胶、山萸肉、山药、党参、沙参共为使药,蒲公英利尿散结、清热解毒,昆布活血散结、软坚化痰,鳖甲滋阴潜阳、退热除蒸、软坚散结,阿胶补血止血、滋阴润燥,山萸肉补益肝肾、收敛固涩,山药补脾养胃、消炎止疼,党参健脾益肺、养血生津,沙参养阴清肺、益胃生津;木糖醇是一种人工合成的食品甜味剂和多功能食品添加剂,具有甜味,辅助用药。
本发明处方组成合理,不含有毒药材,也无配伍禁忌,具有很好的抗炎散结的作用。通过调整君药化橘红、金银花的重量份比例配伍后,能够协同抑制由LPS诱导的炎症反应中TNF-α、iL-6的表达。且原料均为天然舒缓成分,药效温和,安全合理,工艺简单,临床疗效可靠,应用过程中未发生明显毒副作用和不良反应,确保临床疗效,质量可控。
附图说明
为了更清楚地说明本发明实施方式的技术方案,下面将对实施方式中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1是本发明实施例中实验二细胞存活率图。
具体实施方式
为使本发明实施方式的目的、技术方案和优点更加清楚,下面将对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式是本发明一部分实施方式,而不是全部的实施方式。因此,以下对本发明所提供的实施方式的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施方式。基于本发明中的实施方式,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施方式,都属于本发明保护的范围。
本发明提供了一种抗炎散结的中药组合物及其制备方法,具有抗炎散结的作用,以达到治疗与抗炎散结相关的疾病并提高相关疾病临床治疗效果。具体实施方式如下:
本发明提供的一种抗炎散结的中药组合物,包括如下原料:化橘红、金银花、茯苓、薏苡仁、鱼腥草、以生地、白扁豆、佛手、苦杏仁、牡蛎、白术、黄精、白芷、蒲公英、昆布、鳖甲、阿胶、山萸肉、山药、党参、沙参、木糖醇。
作为一种优选的实施方式,按重量份计,包括如下原料:化橘红150~350份,金银花150~350份,茯苓100~300份,薏苡仁100~300份,鱼腥草100~300份,生地30~120份,白扁豆30~120份,佛手30~120份,苦杏仁30~120份,牡蛎30~120份,白术30~120份,黄精30~120份,白芷30~120份,蒲公英20~80份,昆布20~80份,鳖甲20~80份,阿胶5~60份,山萸肉5~60份,山药5~60份,党参5~30份,沙参5~30份,木糖醇5~30份。
作为一种优选的实施方式,按重量份计,包括如下原料:化橘红200~300份,金银花200~300份,茯苓150~250份,薏苡仁150~250份,鱼腥草150~250份,生地50~100份,白扁豆50~100份,佛手50~100份,苦杏仁50~100份,牡蛎50~100份,白术50~100份,黄精50~100份,白芷50~100份,蒲公英30~70份,昆布30~70份,鳖甲30~70份,阿胶10~50份,山萸肉10~50份,山药10~50份,党参10~20份,沙参10~20份,木糖醇10~20份。
作为一种优选的实施方式,按重量份计,包括如下原料:化橘红200~250份,金银花250~300份,茯苓180~220份,薏苡仁180~220份,鱼腥草180~220份,生地50~80份,白扁豆50~80份,佛手50~80份,苦杏仁50~80份,牡蛎50~80份,白术50~80份,黄精50~80份,白芷50~80份,蒲公英30~60份,昆布30~60份,鳖甲30~60份,阿胶10~30份,山萸肉10~30份,山药10~30份,党参10~15份,沙参10~15份,木糖醇10~15份。
本发明还提供了上述抗炎散结的中药组合物在制备抗炎结散的药物中的应用。
本发明还提供了一种抗炎散结的药物,包括上述的抗炎散结的中药组合物和药学上可接受的辅料。
作为一种优选的实施方式,上述药物的剂型为中药汤剂、煎剂、颗粒剂、丸剂、胶囊剂、片剂、茶剂、混悬剂、散剂或口服液。
作为一种优选的实施方式,本发明还提供了上述药物的制备方法,所述药物为丸剂,其制备方法如下:
步骤一,按重量份配比称取原料药,净选,烘干,切制,粉碎,过筛,混合均匀;
步骤二,将原料药于清水中浸泡0.5~1h,加热到80-100℃,反复煎煮1~3次,每次加入水的重量为所有原料总重量的10~20倍,加热煎煮时间为1.5~2h,最后合并滤液;
步骤三,静置沉淀滤液后取上清液,浓缩成清膏组合物,喷雾干燥,得到清膏粉,加入炼蜜,按照常规工艺,制成丸剂。
下面结合具体实施方式对本发明作进一步详细说明:
实施例1
一种抗炎散结的药物,其原料药包括:化橘红200份,金银花200份,茯苓150份,薏苡仁150份,鱼腥草150份,生地50份,白扁豆50份,佛手50份,苦杏仁50份,牡蛎50份,白术50份,黄精50份,白芷50份,蒲公英30份,昆布30份,鳖甲30份,阿胶10份,山萸肉10份,山药10份,党参10份,沙参10份,木糖醇10份。其丸剂的制备方法如下:
步骤一,按重量份配比称取原料药,净选,烘干,切制,粉碎,过筛,混合均匀;
步骤二,将原料药于清水中浸泡0.5~1h,加热到80-100℃,反复煎煮1~3次,每次加入水的重量为所有原料总重量的10~20倍,加热煎煮时间为1.5~2h,最后合并滤液;
步骤三,静置沉淀滤液后取上清液,浓缩成清膏组合物,喷雾干燥,得到清膏粉,加入炼蜜,按照常规工艺,制成丸剂。
实施例2
一种抗炎散结的药物,其原料药包括:化橘红200份,金银花250份,茯苓180份,薏苡仁180份,鱼腥草180份,生地50份,白扁豆50份,佛手50份,苦杏仁50份,牡蛎50份,白术50份,黄精50份,白芷50份,蒲公英30份,昆布30份,鳖甲30份,阿胶10份,山萸肉10份,山药10份,党参10份,沙参10份,木糖醇10份。其丸剂的制备方法同实施例1。
实施例3
一种抗炎散结的药物,其原料药包括:化橘红250份,金银花300份,茯苓220份,薏苡仁220份,鱼腥草220份,生地80份,白扁豆80份,佛手80份,苦杏仁80份,牡蛎80份,白术80份,黄精80份,白芷80份,蒲公英60份,昆布60份,鳖甲60份,阿胶30份,山萸肉30份,山药30份,党参15份,沙参15份,木糖醇15份。其丸剂的制备方法同实施例1。
实施例4
一种抗炎散结的药物,其原料药包括:化橘红150份,金银花150份,茯苓100份,薏苡仁100份,鱼腥草100份,生地30份,白扁豆30份,佛手30份,苦杏仁30份,牡蛎30份,白术30份,黄精30份,白芷30份,蒲公英20份,昆布20份,鳖甲20份,阿胶5份,山萸肉5份,山药5份,党参5份,沙参5份,木糖醇5份。其丸剂的制备方法同实施例1。
实施例5
一种抗炎散结的药物,其原料药包括:化橘红300份,金银花300份,茯苓250份,薏苡仁250份,鱼腥草250份,生地100份,白扁豆100份,佛手100份,苦杏仁100份,牡蛎100份,白术100份,黄精100份,白芷100份,蒲公英70份,昆布70份,鳖甲70份,阿胶50份,山萸肉50份,山药50份,党参20份,沙参20份,木糖醇20份。其丸剂的制备方法同实施例1。
实施例6
一种抗炎散结的药物,其原料药包括:化橘红350份,金银花350份,茯苓300份,薏苡仁300份,鱼腥草300份,生地120份,白扁豆120份,佛手120份,苦杏仁120份,牡蛎120份,白术120份,黄精120份,白芷120份,蒲公英80份,昆布80份,鳖甲80份,阿胶60份,山萸肉60份,山药60份,党参30份,沙参30份,木糖醇30份。其丸剂的制备方法同实施例1。
对比例1
一种抗炎散结的药物,其原料药包括:化橘红200份,茯苓180份,薏苡仁180份,鱼腥草180份,生地50份,白扁豆50份,佛手50份,苦杏仁50份,牡蛎50份,白术50份,黄精50份,白芷50份,蒲公英30份,昆布30份,鳖甲30份,阿胶10份,山萸肉10份,山药10份,党参10份,沙参10份,木糖醇10份。其丸剂的制备方法同实施例2。
对比例2
一种抗炎散结的药物,其原料药包括:金银花250份,茯苓180份,薏苡仁180份,鱼腥草180份,生地50份,白扁豆50份,佛手50份,苦杏仁50份,牡蛎50份,白术50份,黄精50份,白芷50份,蒲公英30份,昆布30份,鳖甲30份,阿胶10份,山萸肉10份,山药10份,党参10份,沙参10份,木糖醇10份。其丸剂的制备方法同实施例2。
实验一:采用优选实施例1~3和对比例1~2所制备的药物进行实验鉴定本发明所提供的药物对祛湿散结的效果:
(1)实验动物
SPF级的健康雄性小鼠36只,周龄为7~8周,体重为120~125g,均购自广州中医药大学实验动物中心,饲养于广州中医药大学第一附属医院SPF级动物实验中心,实验环境:20~25℃恒温,相对湿度40~60%,光照循环12小时,自由进食进水,适应性饲喂1周后开始试验。
(2)实验药品
实验原料购于广州中医药大学第一附属医院,经广州中医药大学中药鉴定教研室鉴定,所购药材均符合《中华人民共和国药典》标准,所用辅料符合《中华人民共和国药典》或GB 2760中关于食品添加剂使用标准。
(3)造模与实验分组
36只小鼠适应性喂养1周后,将其随机分为6组,分别为:
①造模组,
②实施例1给药组,
③实施例2给药组,
④实施例3给药组,
⑤对比例1给药组,
⑥对比例2给药组;
将36只小鼠置于温度为25~35℃,湿度为70%~80%的密闭箱子内,连续高脂饲料喂养12天,通过高脂饮食以及高湿环境造构建湿气肥胖模型,随机选取其中6只小鼠作为造模组。其余小鼠随机分为5组,分别为实施例1给药组、实施例2给药组、实施例3给药组、对比例1给药组和对比例2给药组,在造模的基础上,分别对各组灌胃给予实施例1~3和对比例1~2所制备得到的10g丸剂,分为每天早晚两次给药,连续给药14天,并记录实验前和实验结束各组鼠的体重差。造模组则采用正常饮食14天。体重变化见表1。
(3)实验结果
表1各组丸剂对大鼠体重的影响
(P<0.05表示显著性差异(*),P<0.01表示极显著差异(**))
由表1结果可知,针对患有湿气肥胖的小鼠,仅通过正常饮食的体重变化不大,但服用实施例1~3所制备丸剂的小鼠与服用对比例1~2所制备丸剂的小鼠相比,体重下降显著,表明其具有减肥功效,具有祛湿散结的作用。
实验二:采用优选实施例1~3和对比例1~2所制备的药物进行实验鉴定本发明所提供的药物对抗炎的效果:
(1)药物制备
各称取20g上述实施例1~3和对比例1~2所制备得到的丸剂,将其研磨粉碎,并分别加入10mL的水中充分溶解制备得到相应的2g/mL的药物溶液。
(2)构建模型
以每孔1×106个细胞接种RAW264.7细胞于96孔板中,在37℃恒温条件下过夜培养。
(3)正式实验
分别用2g/mL的实施例1~3和对比例1~2得到的药物溶液处理细胞24h,吸弃培养基,加入适量的噻唑蓝(MTT)工作液,置于细胞培养箱内继续孵育2h后,再加入适量终止液,孵育2h后用酶标仪于562nm处测定OD值,计算细胞存活率。得到图1。
(4)实验结果
由图1结果可知,采用上述实施例1~3和对比例1~2的丸剂配置的2g/mL药物溶液均具有良好的生物相容性,细胞存活率均在99.5%以上,且实施例1~3的细胞存活率均高于对比例1~2,可见上述所有丸剂的安全性高,无毒性作用,实施例1~3的安全性更高。
实验三:采用优选实施例1~3和对比例1~2所制备的药物进行实验鉴定本发明所提供的药物对LPS诱导的RAW264.7炎症细胞的抗炎效果:
(1)药物制备
各称取20g上述实施例1~3和对比例1~2所制备得到的丸剂,将其研磨粉碎,并分别加入10mL的水中充分溶解制备得到相应的2g/mL的药物溶液。
(2)构建模型
通过常规技术使用细菌脂多糖(LPS)刺激小鼠单核巨噬细胞RAW264.7细胞,从而构建炎症模型。
(3)正式实验
将RAW264.7细胞以每孔2×106个细胞接种于96孔板中,过夜培养。待细胞贴壁后,将各组的2g/mL的药物溶液添加到模型细胞中,并添加等量的培养液作为对照组,一起培养24h后,记录在实验前和实验结束后分别使用可检测TNF-α、iL-6炎症因子的市售试剂盒测定相应浓度。浓度变化见表2。
表2各组丸剂对RAW264.7细胞的影响
(P<0.05表示显著性差异(*),P<0.01表示极显著差异(**))
由表2数据结果可知,针对LPS诱导的RAW264.7炎症细胞,服用单独以化橘红为君药的丸剂配制溶液的对比例1和单独以金银花为君药的丸剂配制溶液对比例2均具有减少炎症细胞中TNF-α、iL-6炎症因子的作用,具有显著的统计学意义。但实施例1~3的丸剂配制溶液抗炎效果更为显著,且采用金氏公式评价化橘红、金银花的联合配伍用药的作用,常规的金氏公式规定其Q<0.85具有拮抗作用,0.85≤Q≤1.15具有相加作用,Q>1.15具有协同作用。
通过计算实施例2的丸剂配制溶液的Q值可知,针对TNF-α的Q=1.456;针对iL-6炎症因子的Q=1.712,其Q均大于金氏公式规定的Q>1.15,可见,实施例3的丸剂配制溶液对抑制LPS刺激促进RAW264.7细胞炎症因子的释放具有协同作用。
典型案例:
案例1:
患者何某,男,55岁,肺部结节1年余。2023年8月来院就诊,检查胸部CT提示左上肺结节,大小约0.6×0.8cm,临床表现为反复咳嗽白痰,偶有气促胸闷,大便粘腻不爽,经常偏烂,小便清长,纳眠一般,舌淡红,苔白腻,脉滑数。中医诊断:积病、脾虚痰湿证;西医诊断:肺部结节;口服含本发明提供实施例2的中药复方提取膏方制剂,每日两次,每次10~15g,餐后服用,服用28天为1疗程,连续服用3疗程。服用1疗程后咳嗽咳痰明显减轻,无诉气促胸闷,大便逐步成形,舌淡红,苔薄白,脉滑。2023年11月本院复查胸部CT提示左上肺结节0.5×0.6cm,未见新发病灶。结果表明,本药方能够有效缓解肺部结节患者咳嗽咳痰等胸部症状,同时可以使肺结节病灶有所缩小,对脾虚痰湿型结节病患者有良好临床效果。
案例2:
患者骆某,女,76岁,甲状腺结节10年余,于国外医院2次甲状腺肿物切除。2024年3月来院就诊,检查甲状腺B超提示甲状腺肿大,多发结节,最大病灶约2.6×3.2cm,临床表现为颈部肿胀,反复咽喉不适,胸隔满闷,咯痰不爽,大便偏烂,纳眠一般,舌暗红,苔白厚腻,脉滑数。中医诊断:积病、脾虚痰瘀证;西医诊断:结节性甲状腺肿;口服含本发明提供实施例2的中药复方提取膏方制剂,每日两次,每次10~15g,餐后服用,服用28天为1疗程,连续服用3疗程。服用1疗程后咽喉不适减轻,胸闷明显改善,服用3疗程后大便逐步成形,舌淡红,苔薄白腻,脉细滑。2024年7月颈部肿胀明显改善,本院复查B超提示最大病灶2.2×2.8cm。结果表明,本药方能够有效缓解结节性甲状腺肿(甲状腺结节)患者咽喉及胸闷不适症状,同时可以使甲状腺病灶明显缩小,对脾虚痰瘀型结节病患者有良好临床效果。
案例3:
患者马某,女性,47岁,乳腺癌术后5月余。患者2023年12月于外院行乳腺手术,术后病理提示浸润性腺癌,术后规范放化疗、内分泌治疗。2024年3月复查提示右侧乳腺结节,大小约0.8×0.9cm,BI-RADS4A类,接诊时除精神焦虑外无明显特殊不适。舌暗红,苔白腻,脉弦滑。中医诊断:积病、脾虚痰瘀证;西医诊断:乳腺恶性肿瘤、乳腺纤维瘤;口服含本发明提供实施例2的中药复方提取膏方制剂,每日两次,每次10~15g,餐后服用,服用28天为1疗程,连续服用3疗程。服用3疗程后患者无特殊情况,舌淡红,苔薄白腻,脉细。2024年8月外院复查B超提示右侧乳腺结节,大小约0.7×0.8cm,BI-RADS3类,原乳腺癌手术部位无异常。结果表明,本药方能够有效治疗乳腺纤维瘤(乳腺结节)病灶,使原有病灶有所缩小降级,对脾虚痰瘀型结节病患者有良好临床效果。
案例4:
患者吴某,男,60岁,肝内囊肿1年余。2023年8月来院就诊,检查肝脏B超及上腹部CT提示肝脏S6病灶,大小约1.6×1.9cm,考虑囊肿。临床表现为右侧胁肋部疼痛,偶有恶心泛酸,大便溏泻不调,纳差眠一般,舌暗红,苔薄白腻,脉弦滑。中医诊断:积病、肝郁脾虚证;西医诊断:肝脏囊肿;口服含本发明提供实施例2的中药复方提取膏方制剂,每日两次,每次10~15g,餐后服用,服用28天为1疗程,连续服用3疗程。服用1疗程后无诉胁肋部疼痛,服用3疗程后大便逐步成形,舌淡红,苔薄白,脉细。2023年11月本院复查B超提示肝内囊肿1.2×1.4cm,未见新发病灶。结果表明,本药方能够有效缓解肝脏占位病灶患者疼痛等胸部症状,同时可以使肝脏囊肿病灶有所缩小,对肝郁脾虚型肝脏囊肿患者有良好临床效果。
以上所述仅为本发明的优选实施方式而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种抗炎散结的中药组合物,其特征在于,包括如下原料:化橘红、金银花、茯苓、薏苡仁、鱼腥草、以生地、白扁豆、佛手、苦杏仁、牡蛎、白术、黄精、白芷、蒲公英、昆布、鳖甲、阿胶、山萸肉、山药、党参、沙参、木糖醇。
2.根据权利要求1所述的抗炎散结的中药组合物,其特征在于,按重量份计,包括如下原料:化橘红150~350份,金银花150~350份,茯苓100~300份,薏苡仁100~300份,鱼腥草100~300份,生地30~120份,白扁豆30~120份,佛手30~120份,苦杏仁30~120份,牡蛎30~120份,白术30~120份,黄精30~120份,白芷30~120份,蒲公英20~80份,昆布20~80份,鳖甲20~80份,阿胶5~60份,山萸肉5~60份,山药5~60份,党参5~30份,沙参5~30份,木糖醇5~30份。
3.根据权利要求1所述的抗炎散结的中药组合物,其特征在于,按重量份计,包括如下原料:化橘红200~300份,金银花200~300份,茯苓150~250份,薏苡仁150~250份,鱼腥草150~250份,生地50~100份,白扁豆50~100份,佛手50~100份,苦杏仁50~100份,牡蛎50~100份,白术50~100份,黄精50~100份,白芷50~100份,蒲公英30~70份,昆布30~70份,鳖甲30~70份,阿胶10~50份,山萸肉10~50份,山药10~50份,党参10~20份,沙参10~20份,木糖醇10~20份。
4.根据权利要求1所述的抗炎散结的中药组合物,其特征在于,按重量份计,包括如下原料:化橘红200~250份,金银花250~300份,茯苓180~220份,薏苡仁180~220份,鱼腥草180~220份,生地50~80份,白扁豆50~80份,佛手50~80份,苦杏仁50~80份,牡蛎50~80份,白术50~80份,黄精50~80份,白芷50~80份,蒲公英30~60份,昆布30~60份,鳖甲30~60份,阿胶10~30份,山萸肉10~30份,山药10~30份,党参10~15份,沙参10~15份,木糖醇10~15份。
5.权利要求1~4任一项所述的抗炎散结的中药组合物在制备抗炎结散的药物中的应用。
6.一种抗炎散结的药物,其特征在于,包括权利要求1~4任一项所述的抗炎散结的中药组合物和药学上可接受的辅料。
7.根据权利要求6所述的抗炎散结的药物,其特征在于,所述药物的剂型为中药汤剂、煎剂、颗粒剂、丸剂、胶囊剂、片剂、茶剂、混悬剂、散剂或口服液。
8.权利要求7所述的抗炎散结的药物的制备方法,其特征在于,所述药物为丸剂,其制备方法如下:
步骤一,按重量份配比称取原料药,净选,烘干,切制,粉碎,过筛,混合均匀;
步骤二,将原料药于清水中浸泡0.5~1h,加热到80-100℃,反复煎煮1~3次,每次加入水的重量为所有原料总重量的10~20倍,加热煎煮时间为1.5~2h,最后合并滤液;
步骤三,静置沉淀滤液后取上清液,浓缩成清膏组合物,喷雾干燥,得到清膏粉,加入炼蜜,按照常规工艺,制成丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202411395437.XA CN119367476A (zh) | 2024-10-08 | 2024-10-08 | 一种抗炎散结的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202411395437.XA CN119367476A (zh) | 2024-10-08 | 2024-10-08 | 一种抗炎散结的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN119367476A true CN119367476A (zh) | 2025-01-28 |
Family
ID=94336869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202411395437.XA Pending CN119367476A (zh) | 2024-10-08 | 2024-10-08 | 一种抗炎散结的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN119367476A (zh) |
-
2024
- 2024-10-08 CN CN202411395437.XA patent/CN119367476A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101249235B (zh) | 治疗食道癌的中药及其制备方法 | |
CN100593417C (zh) | 一种治疗胃癌及骨癌的中药 | |
CN101670056A (zh) | 一种治疗恶性肿瘤的药物 | |
CN101695546B (zh) | 一种治疗消化道癌症的中药及其制备方法 | |
CN103157014B (zh) | 一种治疗肿瘤的苗药 | |
CN101543616B (zh) | 一种防治肿瘤的中药组合物及其制备方法 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN108210657A (zh) | 一种预防和治疗肺癌的中药组合物 | |
CN101954022B (zh) | 一种用于治疗肺癌的中药组合物 | |
CN119367476A (zh) | 一种抗炎散结的中药组合物及其制备方法 | |
CN113368211A (zh) | 一种用于治疗犬猫肿瘤的中兽药组合物及其制备方法 | |
CN102526639A (zh) | 治疗高血脂症的中药组合物及其制备方法 | |
CN101991659A (zh) | 一种具有清热解毒功能的制剂及制备方法 | |
CN105521332A (zh) | 治疗肛裂的中药组合物及其制备方法和应用 | |
CN103720949A (zh) | 通便肠清胶囊及制备方法 | |
CN101708271B (zh) | 一种治疗食管癌的中药 | |
CN102091135A (zh) | 一种含体外培育牛黄的牛黄解毒丸(片、胶囊)及其制备方法 | |
CN101695534B (zh) | 治疗乳腺疾病的中成药 | |
CN102166300B (zh) | 治疗肺部阴虚、胃部阴虚及消渴病阴虚症状的中药制剂 | |
CN101125194A (zh) | 一种用于小儿腹泻的药物组合物 | |
CN119970890A (zh) | 一种治疗乳腺癌合并焦虑症的中药组合物及其制备方法与应用 | |
CN118593652A (zh) | 一种用于转移性非小细胞肺癌的中药组合物 | |
CN114129693A (zh) | 一种治疗癌症的组合物及其制备方法与应用 | |
CN111603501A (zh) | 一种用于原发性肝癌的中药组合物及其应用 | |
CN120241935A (zh) | 一种用于气虚血瘀痰阻型冠心病的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |